Shandong Tianming Pharmaceutical, a GMP-certified leader in advanced API and intermediate manufacturing, will unveil its latest innovations at CPHI China 2025 (June 24-26, Shanghai New International Expo Centre).
Visit us at Booth W2G30 to explore cutting-edge solutions reshaping pharmaceutical synthesis.
As an eight-time exhibitor with proven industry partnerships, we deliver more than products – we offer actionable pathways to:
1/Explore cutting-edge API synthesis technology and break through R&D bottlenecks
2/Unlock customized solutions:
3/Overcome Regulatory Hurdles
4/Global compliance escort, opening up international market access channels
– GLP-1 Agonist Intermediates: >99.9% chiral purity for obesity/diabetes pipelines
– Antibiotic Resistance Fighters: β-lactamase inhibitor scaffolds with 80% oral bioavailability
– On-Demand Synthesis: From R&D samples to commercial batches
With 300+ commercial APIs and 15 years of GMP excellence, Tianming enables partners across 40 countries to overcome synthesis scalability, compliance, and sustainability challenges.
We look forward to seeing you at CPHI China 2025!
Best regards
Sales Team
Shandong Tianming Pharmaceutical Group
This article shares real-world insights from two decades of pharmaceutical process development, focusing on how synthesis route design for complex intermediates directly impacts cost, scalability, impurity control, and regulatory compliance.
Explore key pharmaceutical intermediates for cardiovascular drugs, manufacturing requirements, and global market demand supported by regulatory and industry data.
Crystallization and solid-form control are critical to intermediate quality, scalability, and downstream API performance. This article explores common solid-state challenges, scale-up risks, and why early crystallization expertise at the intermediate stage reduces development and regulatory uncertainty.
Leading provider of high-quality APIs and intermediates. Contact us for innovative solutions and expert support.